Last edition
News about " RYBREVANT FASPRO "
Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer
Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.
RYBREVANT FASPRO | 01/08/2026 | By News Bureau | 129
Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.
RYBREVANT FASPRO | 18/02/2026 | By News Bureau | 150
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy